Revcovi™ (elapegademase-lvlr) – New orphan drug approval
October 5, 2018 - Leadiant Biosciences announced the FDA approval of Revcovi (elapegademase-lvlr) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Download PDF
